Paradoxical prognostic phenomenon of plasma T-cell-derived circulating DNA level in advanced non-small cell lung cancer by Sitthideatphaiboon, P., Santisukwongchote, S., Khunsri, S., Sathitruangsak, C., Chantranuwat, P., Vinayanuwattikun, C., Sriuranpong, V.

Get full text

P0227 Utility of pre-treatment serum amphiregulin in colorectal carcinoma by Chayangsu, C, Kanjanasilp, P, Malakorn, S, Sahakitrungruang, C, Tanasanvimon, S, Sitthideatphaiboon, P, Sriuranpong, V

Get full text

P3.02-076 Glutaminase Inhibitor CB-839 Radiosensitizes KRAS-Mutant Lung Cancer Cells in a LKB1- and KEAP1/NRF2-Pathway Dependent Manner by Sitthideatphaiboon, P., Xiao, Q., Giri, U., Heymach, J.

Get full text

P3.03-28 LKB1 Mutation Status is Associated with Poor Radiation Outcome in Patients with Non-Small Cell Lung Cancer by Sitthideatphaiboon, P., Cobo, A., Poteete, A., Zhang, F., Lui, D., Rinsurongkawong, W., Heymach, J.

Get full text

Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers by Gudikote, Jayanthi P., Cascone, Tina, Poteete, Alissa, Sitthideatphaiboon, Piyada, Wu, Qiuyu, Morikawa, Naoto, Zhang, Fahao, Peng, Shaohua, Tong, Pan, Li, Lerong, Shen, Li, Nilsson, Monique, Jones, Phillip, Sulman, Erik P., Wang, Jing, Bourdon, Jean-Christophe, Johnson, Faye M., Heymach, John V.

Get full text

Abstract 2408: LKB1 and KEAP1/NRF2 pathways cooperatively promote glutamine dependence and vulnerability to glutaminase inhibitors in KRAS-mutant lung adenocarcinoma by Galan-Cobo, Ana, Sitthideatphaiboon, Piyada, Qu, Xiao, Kovacs, Jeffrey J., Poteete, Alissa, Tong, Pan, Cho, Sungnam, Gandhi, Varsha V., Skoulidis, Ferdinandos, Wang, Jing, Heffernan, Timothy P., Heymach, John V.

Get full text